Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: bumblin bob who wrote (180267)	10/21/2008 1:54:05 PM
From: nokomis	1 Recommendation Read Replies (1) \| Respond to of 208838

I barely had a chance to call up TMA again when it starting popping - gonna check the rest. Good luck to us all! ~ Nok

To: bumblin bob who wrote (180267)	10/21/2008 2:16:50 PM
From: ACAN	Read Replies (1) \| Respond to of 208838

[MNKD] back over 50dMA and picking up price and volume.

To: bumblin bob who wrote (180267)	10/21/2008 9:06:53 PM
From: ACAN	Read Replies (2) \| Respond to of 208838

[AOB] American Oriental Bioengineering Completes Two Acquisitions Tuesday October 21, 4:01 pm ET Terminates Prior LOI and Acquires Profitable Holding Company to Strengthen Distribution Network and Retail Presence Acquires Research and Product Development Company to Expedite Product Launches Conference Call Scheduled for October 22, 2008 at 8:00 am E.T. NEW YORK, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB - News; "AOBO"), a leading marketer and manufacturer of pharmaceutical and healthcare products in China, today announced that it has completed the acquisition of Nuo Hua Investment Company Ltd. ("Nuo Hua"), as well as the acquisition of GuangXi HuiKe Research and Development Company Ltd. ("GHK"), in cash transactions totaling $53.1 million. Nuo Hua is a holding company with subsidiaries and affiliated companies that maintain a significant presence in pharmaceutical wholesale and retail distribution in China. AOBO acquired Nuo Hua for $39.5 million after terminating a previously announced, non-binding Letter of Intent to acquire another company in the distribution industry in China, as discussed below. GHK is engaged in pharmaceutical research and product development leading to SFDA approval and expedient product launches in China. The acquired companies are profitable and AOBO believes that the acquisitions will significantly enhance AOBO's distribution platform and product launch capabilities, particularly for new product launches starting in 2009. Tony Liu, Chief Executive Officer of American Oriental Bioengineering stated, "We are very pleased to acquire Nuo Hua and GHK and today's announcement represents a major step toward achieving our goal of becoming one of China's top pharmaceutical companies. Nuo Hua provides us with a diverse range of incremental wholesale and retail distribution opportunities, such as in new top-tier hospitals and rural areas, both of which bolster our long-term growth capabilities. GHK lends the innovation we need to bring new products to market quickly and effectively, and brings us several existing patents, a fantastic team of product specialists, and industry know-how in China's complex pharmaceutical registration process."